Wide-Range, Automated Dabigatran Assay Launched

A new assay kit for dabigatran (Pradaxa) measurement in blood plasma provides automation, higher specificity, and broader working range (currently for research use only).

Diagnostica Stago, Inc., the US subsidiary of hemostasis leader Diagnostica Stago, S.A.S. France (Asnières sur Seine, France), expands its offering for direct measurement of oral anticoagulants (DOACs) with the launch of STA-ECA-II—a next-generation ecarin-based chromogenic assay for dabigatran (Pradaxa). With this addition, Stago offers the only complete portfolio of assays for measurement of DOACs. Automated with barcoded loading on Stago’s high-throughput analyzers, STA-ECA-II enables laboratories an efficient and standardized approach to measure dabigatran in plasma samples.

STA-ECA-II is a highly-specific tool for directly measuring dabigatran (Pradaxa) concentration in plasma and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels. With a wide working range of 15–460 ng/mL and 28-day stability at 2–8 °C, the kit is flexible for a variety of sample testing requirements.

Compared to liquid chromatography-mass spectrometry (LC-MS)-based methods, STA-ECA-II demonstrates excellent correlation for measurement of total dabigatran concentrations. It provides confidence in results across the entire measurement range, with an advantage over other methods, especially for samples with low concentrations.

The STA-ECA-II kit (catalog number 01108), along with the STA-Dabigatran Calibrator (catalog number 01109) and STA-Dabigatran Control (catalog number 01110) products are labeled for research-use-only in the United States and Canada, and are not for use in diagnostic procedures.

Related Links:
Diagnostica Stago 
Diagnostica Stago, US